RESEARCH TRIANGLE PARK, N.C. – June 13, 2018 – Metabolon, Inc., the global leader in metabolomics, today announced that John Ryals, PhD, has retired as its president and chief executive officer, but will remain on the company’s board of directors. Rohan F. Hastie, PhD, previously chief business officer at Metabolon, has been promoted to the role of president and chief executive officer.
Dr. Ryals has served as president, CEO and a board member of Metabolon since April 2002, when he co-founded the company. During his tenure, he built Metabolon into a pioneer and leader in the field of metabolomics and its use in precision medicine and human health.
“We started Metabolon in earnest in 2002, and over the past 16 years Metabolon has grown into the world’s most advanced metabolomics technology company,” said Ryals. “What began as ideas on a white board has grown into a valuable clinical technology that will be essential for precision medicine. In my role as a board member and chair emeritus, I will continue to help Metabolon wherever I can and give my full support to Rohan as he transitions into his new role.”
In addition to Metabolon, Dr. Ryals currently serves on the board of directors at AgBiome LLC and Phytelligence and the advisory board of the College of Agriculture and Life Sciences at North Carolina State University.
Dr. Hastie joined Metabolon in September 2017 as chief business officer, leading the company’s global commercialization efforts. Prior to joining, he was president of Arrow Life Sciences & Healthcare, a consulting firm specializing in commercialization and operational excellence for life sciences companies. Dr. Hastie also held senior leadership positions in diagnostics and corporate development at Hologic, Inc. and most recently served as president of Hologic Diagnostic Solutions. Before Hologic, he worked at the strategy consulting company PA Consulting Group in their Life Sciences and Technology group, where he served a wide range of companies in the pharmaceutical, biotechnology and diagnostics industries. Dr. Hastie has a PhD in molecular genetics from Queen Elizabeth Medical School in Birmingham UK and a degree in biological sciences from the University of Birmingham.
“Metabolon is at the forefront of the industry, having performed more studies and generated more data than any other company in our space, which will be key to unlocking systems biology and enabling the translation of diverse biological and multi-omics data sets,” said Hastie. “John has been instrumental in building the technology that will empower us and our clients to continue making discoveries that will lead to better health outcomes. It is a very exciting time for Metabolon as we begin to apply artificial intelligence to the data. We envision shaping metabolomics into one of the most valuable technologies impacting life sciences research, drug discovery and development, diagnostics, wellness and therapy response.”
Cautionary Note about Forward-Looking Statements
The materials provided herein that are not historical facts are or might constitute projections and other forward-looking statements regarding future events that involve substantial risks, uncertainties and assumptions. If any of these risks or uncertainties materialize, or if any of these assumptions prove to be incorrect, Metabolon’s results could differ materially from the results expressed or implied by any forward-looking statements. The risks, uncertainties and assumptions referred to above include, but are not limited to: the uncertainties inherent in biochemical research and development; decisions by regulatory authorities regarding whether and when to approve diagnostic tests; the clinical utility of Metabolon’s metabolomic services; Metabolon’s and its distributors’ ability to successfully commercialize and market both new and existing products; governmental laws and regulations affecting health care, including access, pricing and reimbursement of diagnostic tests; the strength of Metabolon’s intellectual property portfolio; Metabolon’s history of operating losses; whether Metabolon is able to achieve or sustain profitability; its highly competitive industry; its ability to compete effectively; security and privacy risks; and Metabolon’s ability to continue to innovate and provide products and services that are useful to its clients, among other risks, uncertainties and assumptions.
